ArticleMedical molecular morphology2018
Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor.
Article in Medical molecular morphology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Pooled it
- Molecular and immune characteristics of neuroendocrine bladder carcinoma - Implications for diagnosis, prognosis, and therapy: A review.Biomolecules & biomedicine · 2025Review
- Review
- Deep sequencing reveals distinct microRNA-mRNA signatures that differentiate pancreatic neuroendocrine tumor from non-diseased pancreas tissue.BMC cancer · 2025Article
- Insulinoma-associated protein-1 (INSM-1) is a useful diagnostic marker for the evaluation of primary thymic neuroendocrine neoplasms: an immunohistochemical study of 27 cases.Virchows Archiv : an international journal of pathology · 2025Article
- [Neuroendocrine tumors].Pathologie (Heidelberg, Germany) · 2025Review
- Diagnostic and prognostic utility of insulinoma-associated protein 1, insulin gene enhancer protein 1, and secretagogin in pheochromocytoma.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Comparison of insulinoma-associated protein 1 (INSM1) with traditional neuroendocrine markers in gastrointestinal and pancreatic mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs).Diagnostic pathology · 2024Article
- Comparison among different preclinical models derived from the same patient with a non-functional pancreatic neuroendocrine tumor.Human cell · 2024Article
- High expression of insulinoma-associated protein 1 (INSM1) distinguishes colorectal mixed and pure neuroendocrine carcinomas from conventional adenocarcinomas with diffuse expression of synaptophysin.The journal of pathology. Clinical research · 2023Article
- [Expression and significance of INSM1 and SOX11 in pancreatic neuroendocrine tumor and solid pseudopapillary neoplasm].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2023Article
- Review
- INSM1 promotes breast carcinogenesis by regulating C-MYC.American journal of cancer research · 2023Article
- Co-Expression of Adaptor Protein FAM159B with Different Markers for Neuroendocrine Cells: An Immunocytochemical and Immunohistochemical Study.International journal of molecular sciences · 2022Article
- Immunohistochemical analyses of the expression profiles of INSM1, ATRX, DAXX and DLL3 in solid papillary carcinomas of the breast.Oncology letters · 2022Article
- Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls.Virchows Archiv : an international journal of pathology · 2022Review
- INSM1 Expression in Mesenchymal Tumors and Its Clinicopathological Significance.BioMed research international · 2022Article
- Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review).Experimental and therapeutic medicine · 2021Review
- Mesenchymal/non-epithelial mimickers of neuroendocrine neoplasms with a focus on fusion gene-associated and SWI/SNF-deficient tumors.Virchows Archiv : an international journal of pathology · 2021Article
- INSM1 Expression in Breast Neoplasms with Neuroedocrine Features.Endocrine pathology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulinoma-associated protein 1 (INSM1) is an important biomarker of Achaete-scute homolog-like 1-driven pathways. For diagnosis of pancreatic neuroendocrine tumors (PanNET), chromogranin A (CGA), synaptophysin (SYP), and neural cell adhesion molecule (NCAM) were also considered as potential biomarkers. However, it is often difficult to diagnose it immunohistochemically. Hence, we examined the expression pattern of INSM1 in pancreatic solid tumors. We detected INSM1, CGA, SYP, and NCAM immunohistochemically, in 27 cases of NET [pure type: 25 cases, mixed adenoneuroendocrine carcinoma (MANEC): 2 cases]. We included 5 cases of solid-pseudopapillary neoplasm (SPN), 7 cases of acinar cell carcinoma (ACC), and 15 cases of pancreatic ductal adenocarcinoma (PDAC) as the control group. Nuclear expression of INSM1 was found in all PanNET pure type cases. However, expression of INSM1 was negative in PDAC, ACC, and SPN in all cases, whereas faint expression was seen in the cytoplasm from SPN. MANEC comprises of two components: neuroendocrine carcinoma and adenocarcinoma components. The NET component was positive for INSM1 expression, whereas the PDAC component does not express INSM1, which aids in distinguishing these components. Our results suggest that INSM1 is a useful immunohistochemical marker for diagnosing pancreatic neuroendocrine tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.